Skip to NavigationSkip to content

life sciences

Scotland's life sciences sector on track to break $8 billion by 2025

A new report from the Scottish Government has revealed that the country’s life sciences sector is on track to breeze past its turnover target of $8 billion by the year 2025, thanks to strong and consistent growth over the past seven years.

According to the report, the value of the sector hit $6.5 billion by 2017 – a growth of 90% since 2010, increasing 9.6% year on year. Gross value added (GVA) also grew by 48% at an annual rate of 5.7%.

Over this same period, employment at life sciences companies in Scotland increased by 20% at a rate of 2.6% a year.

GSK veteran Dave Tudor joins MMIC in Scotland

Published on: 09/11/18

GlaxoSmithKline veteran, Dave Tudor, is set to take on the role of Managing Director of the Medicines Manufacturing Innovation Centre (MMIC), a new manufacturing centre designed to increase the speed and cost effectiveness of the process through which medicines are brought to market. The facility is set to be built in Renfrewshire, Scotland over the next two years.

The value of measuring biotech Board performance

Published on 04/10/18 at 12:06pm

Nick Stephens of The RSA Group discusses the importance of stopping to quantify the effectiveness of board members within life sciences, and offers guidance on how to manage this effectively.

The measurement underpinning government goals for UK life sciences

Published on 22/01/18 at 11:51am
Image Credit: Nicolas Raymond,

Michael Adeogun, Head of Life Sciences and Health at National Physical Laboratory, discusses the importance of effective measurement for the life sciences industry in achieving the key goals outlined in Sir John Bell’s Life Sciences Industrial Strategy, the UK Government’s accompanying Sector Deal and beyond.

UK government unveils pharma research HQ coup

The UK government’s Autumn Budget struck a gloomy note for the economy, with figures pointing towards low productivity and the likelihood of slowing growth in the years to come.

With Brexit negotiations progressing at a snail’s pace, the government needed a boost to show that its economic plans were proving fruitful and they have released news that will allow them to claim some success.

Could the new EU Medical Devices Regulation put the UK MedTech industry in peril?

Published on 28/09/17 at 10:07am

Gill Jennings and Every's Fiona Stevens discusses recent developments in medical devices regulation and the subsequent impact on IP and investment in the medtech sector.

Alzheimer’s disease: Fighting back against a growing threat

Published on 11/09/17 at 11:09am

September marks Alzheimer’s Awareness Month, a crucial calendar period as the global threat of the disease slowly grows. To mark the occasion, Pharmafocus spoke to experts at two of the UK’s most foremost institutions devoted to Alzheimer’s research.

Carol Routledge, Director of Research at Alzheimer’s Research

What message would you like to share during this month?

Merck KGaA commits to continued partnership with Ugandan Government

Merck KGaA has revealed plans to continue its commitment to a key partnership with the Ugandan Government via its non-profit subsidiary Merck Foundation to build healthcare capacity and treatment access in the region, particularly in the areas of cancer, cardiovascular disease, diabetes and infertility.

Top Ten most popular articles on this week

This week saw the news of a breakthrough in bispecific antibody production and Merck KGaA finally secured approval for its multiple sclerosis drug after seven years.

Also big news was the release of a government commissioned sector report authored by Sir John Bell, Professor of medicine at the University of Oxford, which sets out how life sciences can form a core part of the UK economy as the UK's divorce from the EU nears.

NICE rejects AstraZeneca's breast cancer drug Faslodex

NICE has announced its decision to not recommend AstraZeneca’s breast cancer drug Faslodex (fulvestrant) in women who have oestrogen-receptor-positive, locally advanced breast cancer or breast cancer that has spread to other parts of the body, who have not already had treatment with hormonal therapy (aromatase inhibitors or tamoxifen).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches